Latest stories
-
Inside AbbVie’s High-Stakes Neuro Portfolio and Pipeline Strategy
Following recent neuro-pharmaceutical acquisitions and drug approvals, we assess AbbVie’s pipeline strategy, financial impact, and key shareholder risks.
-
US I-Bonds Hit 5.51% Rate, Highest Fixed Component in Two Decades
New Series I savings bonds offer a 1.40% fixed rate, the highest since 2006, as inflation remains sticky and savers seek tax-advantaged…
-
Bristol Myers Squibb vs Vertex: Investment Merits Compared Ahead of 2027
Analysis of financial performance and sector trends pits steady value Bristol Myers Squibb against high-growth Vertex Pharmaceuticals for personal finance readers ahead…
-
The $1,500-a-Year GLP-1 Drug Threat to Retirement Savings
Half of GLP-1 users face choosing medication over retirement savings as out-of-pocket costs top $1,500 annually.
-
Lenacapavir PrEP Costs $42,250 a Year in the U.S. Versus $60 for Generic Pills
The twice-yearly injection keeps 86% of users adherent versus 46% for daily pills, but the wholesale price gap exceeds $42,000 annually for…
-
How Missing Bank Statements Trigger Medicaid Denials and $41,000 Bills for Nursing Home Residents
A nursing home files a Medicaid application as a courtesy but omits three bank statements, leaving the family liable for four months…
-
Claude’s New Personal Finance Tool Lets Users Spot Spending Leaks via Chat
Anthropic’s new feature connects to bank accounts via Plaid, allowing users to ask conversational questions to categorize spending and flag duplicate charges.
-
Why ACA Premiums Are Rising Again in 2027
Double-digit premium hikes return as federal subsidies expire and healthcare costs climb, leaving middle-income families facing higher bills and fewer options.
-
How a $310,000 Investment Gain Can Boost Medicare Premiums for Retirees
A retiree’s capital gains from selling investments can trigger higher Medicare Part B premiums two years later, a surprise cost many overlook.
-
Inovio’s First FDA Approval Tests Whether DNA Medicines Can Pay Off for Retail Investors
Voceryq’s accelerated approval for a rare throat disease gives the Plymouth Meeting biotech its first product revenue, but confirmatory trials and a…
-
High-Yield Savings Rates Reach 4.70% on November 3
New rates up to 4.70% offer a real return on cash reserves, far outpacing the national average of 0.38% and protecting savings…
-
Personal Factors Driving Cancer Biomarker Decisions and Patient Outcomes
Gosselaar’s campaign highlights how personal health history and financial access shape biomarker testing choices and treatment precision.
-
Affluent Investors Over 60 Face Tax Risks When Splitting Assets
Affluent retirees over 60 must navigate complex tax implications when dividing their wealth, with Roth conversions and 401(k) withdrawals posing significant financial…
-
Nicole Eggert’s Cancer Bills and a Trial That Cut Financial Toxicity for Patients
Despite insurance, out-of-pocket costs and lost wages create fiscal survival challenges for patients, as seen in Nicole Eggert’s battle.
-
Could the Moderna-Merck Melanoma Vaccine Win FDA Approval Within Two Years? What We Know
Intismeran met primary endpoints in phase 3, but FDA filing date remains unannounced as companies race toward potential 2027 approval.
-
Why Retirees Must Shift Emergency Fund Strategies Beyond Standard Three-Month Rules
Retirees face unique spending shocks like home repairs and medical costs, requiring a shift from salary-based savings to portfolio-based liquidity buffers.
-
Why Personal Bankruptcies Jumped 11% Despite Economic Growth
Rising credit costs and eroded savings are driving more Americans to bankruptcy even as GDP expands and unemployment remains low.
-
How Lendmark Financial Services Is Expanding Access to Credit in Local Markets
As Lendmark Financial Services grows its branch network across the Southeast, here is how the lender is shaping personal finance options for…
-
Four in 10 US Adults Carry Health Care Debt as Michigan Wipes Another $21 Million
Learn how insured patients can navigate hospital billing departments, leverage legal protections, and manage unexpected medical debt.
-
How Private Credit Facilities Expand Access to Affordable Consumer Lending
Examining how institutional credit partnerships like Viola Credit’s latest deal influence the personal finance landscape and fair lending availability.
-
A $30 Estate-Sale Painting Fetched $1.35 Million: The Tax Hits a Retiree Could Face
A recent auction win highlights how selling unique assets can trigger complex state and federal tax liabilities, potentially draining retirement savings.
-
Rural Cancer Death Gap Persists as National Rates Fall, Reports Show
For nearly three decades, the United States has seen cancer death rates fall. The turnaround began in 1991. But the gains have…
Most read
-
Martin Lewis Warns Savers With £10,000 or More They Could Owe Tax on Interest
-
Asian & Oceanian Epilepsy Congress 2026 in Kuala Lumpur
-
Baby & Beyond Maternity Expo in Kuala Lumpur 2026
-
Axos Offers 5.00% Savings Rate for Six Months After Fed Hike, With Strings Attached
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
FDA orders class-wide GLP-1 label update for rare eye disease risk
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
-
Understanding Metastatic Prostate Cancer Prognosis and Modern Treatment Pathways
-
Nangibotide Targets Acute-on-Chronic Liver Failure With Phase 2 Data Due 2027
-
SABR Versus Surgery: New Study Reveals Mortality Gap for Early-Stage Lung Cancer
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992
























